Bicara Therapeutics (NASDAQ:BCAX) Stock Price Expected to Rise, The Goldman Sachs Group Analyst Says

Bicara Therapeutics (NASDAQ:BCAX) had its price objective raised by analysts at The Goldman Sachs Group from $14.00 to $16.00 in a research note issued on Tuesday,Benzinga reports. The brokerage presently has a “neutral” rating on the stock. The Goldman Sachs Group’s target price would suggest a potential downside of 21.95% from the stock’s previous close.

A number of other equities analysts have also recently issued reports on BCAX. Weiss Ratings reissued a “sell (d-)” rating on shares of Bicara Therapeutics in a report on Friday, January 9th. BTIG Research reaffirmed a “buy” rating on shares of Bicara Therapeutics in a research note on Thursday, January 15th. Wells Fargo & Company upped their price target on Bicara Therapeutics from $11.00 to $16.00 and gave the company an “equal weight” rating in a research report on Tuesday. Mizuho upgraded Bicara Therapeutics to a “hold” rating in a research note on Thursday, December 18th. Finally, UBS Group reissued a “buy” rating on shares of Bicara Therapeutics in a report on Wednesday, January 14th. Eight analysts have rated the stock with a Buy rating, three have issued a Hold rating and one has issued a Sell rating to the company. According to data from MarketBeat.com, Bicara Therapeutics has an average rating of “Moderate Buy” and an average price target of $28.00.

Bicara Therapeutics Stock Performance

Shares of Bicara Therapeutics stock opened at $20.50 on Tuesday. The firm has a market cap of $1.34 billion, a P/E ratio of -8.10 and a beta of -1.24. The firm’s 50-day simple moving average is $17.28 and its 200-day simple moving average is $16.69. Bicara Therapeutics has a twelve month low of $7.80 and a twelve month high of $21.05.

Bicara Therapeutics (NASDAQ:BCAX) last posted its quarterly earnings results on Monday, March 30th. The company reported ($0.68) earnings per share (EPS) for the quarter, topping the consensus estimate of ($0.72) by $0.04. On average, equities analysts forecast that Bicara Therapeutics will post -2.59 earnings per share for the current fiscal year.

Insiders Place Their Bets

In related news, CEO Claire Mazumdar sold 36,766 shares of the firm’s stock in a transaction on Monday, March 9th. The stock was sold at an average price of $19.17, for a total transaction of $704,804.22. Following the completion of the sale, the chief executive officer directly owned 339,392 shares of the company’s stock, valued at $6,506,144.64. This trade represents a 9.77% decrease in their position. The transaction was disclosed in a document filed with the SEC, which is available at this hyperlink. Also, COO Ryan Cohlhepp sold 17,392 shares of Bicara Therapeutics stock in a transaction on Tuesday, March 3rd. The shares were sold at an average price of $18.16, for a total value of $315,838.72. Following the completion of the transaction, the chief operating officer owned 205,141 shares of the company’s stock, valued at approximately $3,725,360.56. The trade was a 7.82% decrease in their position. The SEC filing for this sale provides additional information. Insiders sold 137,969 shares of company stock valued at $2,586,198 over the last quarter. 15.50% of the stock is owned by insiders.

Institutional Trading of Bicara Therapeutics

Several large investors have recently made changes to their positions in the business. Vestal Point Capital LP increased its stake in shares of Bicara Therapeutics by 2.0% in the third quarter. Vestal Point Capital LP now owns 5,100,000 shares of the company’s stock valued at $80,529,000 after buying an additional 100,000 shares in the last quarter. T. Rowe Price Investment Management Inc. lifted its position in Bicara Therapeutics by 596.5% during the 4th quarter. T. Rowe Price Investment Management Inc. now owns 3,236,595 shares of the company’s stock worth $54,472,000 after buying an additional 2,771,868 shares in the last quarter. Janus Henderson Group PLC bought a new stake in Bicara Therapeutics during the 4th quarter worth about $44,484,000. Vanguard Group Inc. grew its holdings in Bicara Therapeutics by 9.8% during the 3rd quarter. Vanguard Group Inc. now owns 2,200,925 shares of the company’s stock worth $34,753,000 after acquiring an additional 195,667 shares during the last quarter. Finally, State Street Corp increased its position in Bicara Therapeutics by 179.5% in the 4th quarter. State Street Corp now owns 1,649,537 shares of the company’s stock valued at $27,762,000 after acquiring an additional 1,059,260 shares in the last quarter.

Key Headlines Impacting Bicara Therapeutics

Here are the key news stories impacting Bicara Therapeutics this week:

• Positive Sentiment: Wall Street analyst consensus implies a large upside (~54.9%) to BCAX based on average price targets and improving earnings-estimate revisions, a factor traders cite as justification for buying interest. Wall Street Analysts Believe Bicara Therapeutics Inc. (BCAX) Could Rally 54.85%: Here’s is How to Trade
• Positive Sentiment: Clinical progress: Seeking Alpha reiterates a Buy rating as BCAX advances its pivotal phase 3 FORTIFI-HN01 study; strong phase 1/1b signals (12‑month OS 61%, ORR 54% with ficerafusp alfa + KEYTRUDA) support the program. Key upcoming catalysts: phase‑3 interim readout mid‑2027 and long‑term phase 1b follow‑up at ASCO 2026. Near‑full enrollment expected by year‑end. Bicara: Maintaining ‘Buy’ Rating On Ficerafusp Alfa Phase 3 Advancement
• Positive Sentiment: Q4 / cash position: Earnings call highlights show a stronger cash position and a slight beat on Q4 EPS vs. estimates, which reduces near‑term dilution risk and supports runway for clinical execution. Bicara Therapeutics Inc (BCAX) Q4 2025 Earnings Call Highlights
• Neutral Sentiment: Full Q4 earnings call transcript is available for investors digging into management comments on timelines and cash burn; useful for detailed diligence but not a single price driver by itself. Q4 2025 earnings call transcript
• Negative Sentiment: Mixed analyst views: Goldman Sachs raised its PT to $16 (neutral) and Wells Fargo to $16 (equal‑weight)—both targets sit well below the current market price, implying downside from their perspective. These conservative calls can cap near‑term upside and add volatility. Benzinga coverage of analyst moves
• Positive Sentiment: Other broker support remains bullish: Wedbush (outperform, $30 PT), Citizens Jmp (market outperform, $31 PT) and HC Wainwright (buy, PT $42) provide higher upside scenarios that likely underlie investor optimism. Benzinga coverage of analyst moves

Bicara Therapeutics Company Profile

Bicara Therapeutics is a clinical-stage biopharmaceutical company dedicated to developing novel neurohormone-based therapies for psychiatric and neurological disorders. The company’s research focuses on harnessing endogenous signaling pathways in the brain, with the goal of offering new treatment options for conditions that remain inadequately addressed by existing medications. Bicara applies proprietary peptide engineering and intranasal delivery platforms to optimize central nervous system uptake and therapeutic effect.

The company’s lead candidates include PST-001, an intranasal vasopressin-1A receptor antagonist in development for postpartum depression, and PST-002, an oxytocin receptor modulator being investigated for social anxiety and autism spectrum disorder.